Evidence map›Paper›PMID 41144709›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Longitudinal Evaluation of an Abbreviated Patient-Reported Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease.

Mohammad Samsul Alam, Luowen Yu, Glenn T Stebbins, Tiago A Mestre, Christopher G Goetz, Sheng Luo

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammad Samsul AlamDepartment of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-0602-5861
Luowen YuDepartment of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA.
Glenn T StebbinsDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
Tiago A MestreDivision of Neurology, Department of Medicine, Ottawa Hospital Research Institute University of Ottawa Brain and Mind Research Institute, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0002-6973-7479
Christopher G GoetzDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
Sheng LuoDepartment of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0003-4214-5809

Funding

Integrative modeling and dynamic prediction of Alzheimer's diseaseR01AG064803 · NIA · DUKE UNIVERSITY · PI LUO, SHENG · 2020 to 2024
$2.3M
International Parkinson and Movement Disorder SocietyNIA NIH HHS R01 AG064803NIA NIH HHS R01AG064803
6 · The paper itself

Abstract

backgroundPredicting initiation of dopaminergic therapy in early Parkinson's disease (PD) is important for clinical management and trial design. Prior cross-sectional work identified a six-item patient-reported subset from the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts IB + II, but its longitudinal utility is unknown.

objectivesTo test whether modeling longitudinal symptom trajectories improves prediction of dopaminergic therapy initiation beyond baseline-only models, and to identify an abbreviated patient-reported subset with stable prognostic value and utility for trial stratification.

methodsData were harmonized from 1787 untreated early PD patients across six multicenter studies. All 20 MDS-UPDRS Parts IB + II items were analyzed using a longitudinal item response theory model. Items were ranked by discrimination and information functions, and cumulative subsets evaluated in Cox models with time-dependent covariates, adjusted for age, sex, disease duration, and Hoehn and Yahr stage. Predictive accuracy was quantified by concordance index (C-index) for full follow-up and truncation at 1 and 2 years. Risk stratification was assessed based on baseline abbreviated subset scores using Kaplan-Meier analyses.

resultsAn 11-item model consistently outperformed the full 20-item scale (C-index 0.609 vs. 0.597, P < 0.001 with full follow-up; 0.621 vs. 0.599, P < 0.001 at 1 year; 0.615 vs. 0.602, P < 0.001 at 2 years). Longitudinal updates improved discrimination over baseline-only models (eg, 0.609 vs. 0.594 for full follow-up). Higher baseline 11-item scores were strongly associated with earlier therapy initiation.

conclusionsLongitudinal symptom modeling improves prediction of therapy initiation in early PD. An abbreviated 11-item patient-reported MDS-UPDRS provides stronger prognostic value than the full scale and supports trial stratification and clinical monitoring. © 2025 International Parkinson and Movement Disorder Society.

Indexed as

Antiparkinson AgentsDopamine AgentsParkinson DiseaseSeverity of Illness IndexAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedPatient Reported Outcome MeasuresAntiparkinson AgentsDopamine Agentsclinical predictionParkinson's progressionpatient‐reported outcomes

Identifiers

PMID41144709
PMCPMC12597095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.